This qualitative study explored healthcare experiences, unmet needs, and barriers to healthcare access among people with severe and very severe ME/CFS, their family/lay caregivers, and healthcare professionals in Austria.
@kahryn_hoffmann
https://t.co/1No1x0klpS
Presentations on November 18th will focus on pathogen persistence in Infection-Associated Chronic Disease, next-generation diagnostic tests to detect persistence, and innovative treatments that support immune function.
Excited to announce that Simmaron Research has received a new NIH grant to advance our research into understanding the role of mTOR activation in the pathogenesis of ME/CFS.
This award represents an important milestone in our efforts to unravel the underlying molecular mechanisms of this complex and debilitating disease and identify potential new therapeutic targets.
We are grateful to everyone who has contributed to making this research possible and look forward to the discoveries ahead!
Explore the grant on NIH RePORTER:
https://t.co/Ncnel3hCBO
First time I’ve seen someone at a protest, actually speak with the correct amount of anger when discussing ME.
We need more of this and we need it to end up in front of the relevant people in person, not just online.
@lifeanalytics I was very severe back then, mild now. Fucoidan I could try again, though doubt it would do much for me. SPMs I wouldn’t touch if someone paid me.
@lifeanalytics Fucoidan was helpful for alleviating blood congealing & hypoxia in PEM.
When I later tried tocotrienols to reverse the effect of SPMs particularly on macrophages, fucoidan increased my internal vibrations quite violently (but only for a few hours each time)
(cont’d)
Them: Did you know that people in #longCOVID trials have extremely high placebo rates? Really makes you think….
Me: Oh yeah? What placebo did they use?
Them: Nothing crazy, just IV saline
Me: 😐😠😡🤬
I wish people understood pathophysiology.
Excited to announce our results from the first ever survey on GLP-1s for Long COVID and ME!
Patient outcomes showed two extremes: while 53% improved, 28% experienced worsening, some long after their last dose.
Full analysis here and in the tweets below:
https://t.co/SIULpsJkEl
The FSS, like any other tool, is great when applied for its purpose. However, just a quick look at each individual items suggests we would not suspect at least half of them to budge with treatment. This raises the possibility of false negative results from using the wrong tool.
This raises an important point. We often must use measures governments would recognize from other areas of research because PEM-specific measures are so early in psychometric development. However, fatigue surveys do not have adequate content validity for PEM. #ContentValidityGap
Over 500 people will run for ME/CFS research this Saturday at Salzburg’s Volksgarten!🏃
100% of donations go directly to WE&ME and into biomedical ME/CFS research.
If you’d like to cheer on the runners or support with signs, come to the WE&ME tent at Salzburg Volksgarten from 5 PM onward: https://t.co/XVN7OtRiD6
This whole event is organized by volunteers! A huge thank you to everyone who helped promote the Salzburg ME/CFS charity run over the past months. Special thanks to Regina Leimüller, @kimbie_humer, and @ElkeAsen! 💙
If you are a loved one of an ME/CFS patient, please consider volunteering and fundraising for our common cause!🙏
Really big news!!! 👇
First oral pill that's been shown to work as a post-exposure prophylactic to SARS-CoV-2!
The @US_FDA has set a decision date of June 16, 2026 for Xocova.
Excellent piece.
No-one expects people w/ heart disease or asthma to have to read scientific papers to understand their condition, diagnose themselves, & crowdsource research into better treatments.
It's rightly seen to be the job of the health system.
So why not for Long Covid?
Three of the five initial #LongCOVID clinical trials from the NIH RECOVER program have started sharing results, all finding the interventions they tested did not significantly improve symptoms compared to placebos. Read more from @betsyladyzhets: https://t.co/lCLjhEKh1b
Researchers and 2,000+ exposed household contacts found the antiviral ensitrelvir cut symptomatic COVID from 9% to 3% after exposure.
The first pill shown to prevent COVID before symptoms begin.
https://t.co/hETXG3Ax3r
Even when inflammation was initiated prior to addition of mitoDAMPs, IFN-g production was extinguished, suggesting that mitoDAMPs induce a dominant program that prevents IFN-g production.
MitoDAMPs are a heterogeneous mixture of products released from the mitochondria. Relatively few components have been identified and studied, but they have informed the receptor ligand partnerships that govern activation of innate immune cells.
These posts are for you @aubreydegrey re our conversation.
You can remove obvious inflammatory exposure.
It will not matter.